Prof. Dr. Dirk Grimm
- 2017 – Full professor for viral vector technologies, Heidelberg University Hospital
- 2007 – PI of Research Group “Virus-host interactions”, Heidelberg University Hospital, CellNetworks
- 2006 – 2007 Research Associate, Stanford University, School of Medicine, CA, USA
- 2001 – 2006 Postdoctoral Fellow, Stanford University, School of Medicine, CA, USA
- 1999 – 2001 Postdoctoral Fellow, German Cancer Research Center, Heidelberg, Germany
- 1998 PhD (Biology) with Summa cum laude, University of Heidelberg, Germany
- 1994 Diploma (Biology), University of Kaiserslautern, Germany
- 1988 – 1994 Studies in Biology (Universities of Kaiserslautern and Heidelberg, Germany)
Honors and Awards
- 2020 Outstanding Achievement Award (Dutch Society of Gene & Cell Therapy, NVGCT)
- 2017 Research Award (German Duchenne Foundation)
- 2015 Outstanding New Investigator Award (American Society of Gene & Cell Therapy, ASGCT)
- 2010 Gold medal at iGEM (internationally genetically engineered machines) student contest
- 2007 3rd place among “Top 13 Medicine Stories 2006” by Discover Magazine
- 2007/6/4 Travel grants from American Society of Gene Therapy (ASGT)
- 2006 Lecture at Presidential Symposium of ASGT meeting
- 1998 Graduation with “summa cum laude” (PhD with highest honors)
- 1995 – 1998 PhD student grant from Progen Biotechnik GmbH, Heidelberg
Memberships & coordinating functions
- 2020 – German Society of Gene & Cell Therapy (DG-GT)
- 2013 – Editorial Board of “Molecular Therapy – Methods & Clinical Development”
- 2013 – European Society of Gene & Cell Therapy (ESGCT)
- 2012 – Editorial Board of “Molecular Therapy – Nucleic Acids”
- 2013 – 2017 Representative of junior group leaders in HMLS (Heidelberg Molecular LIfe Sciences) Research Council
- 2012 – 2017 Co-coordinator and co-speaker of CellNetworks EcTop5 “Non-coding RNAs as versatile regulators of cellular processes”
- 2011 – 2017 ASGCT “Education Committe”
- 2010 – 2013 ASGCT “Oligonucleotide & RNAi Therapeutics Committee”
- 2002 – American Society of Gene & Cell Therapy (ASGCT)
- Adeno-associated virus (AAV) vectors – Creation and use of synthetic AAV vectors for human gene therapy
- RNA interference (RNAi) – Natural mechanisms and therapeutic/diagnostic applications in mammals and humans
- Infectious diseases – HIV, Hepatitis viruses (HBV, HCV, HDV, HEV), SARS-CoV-2, Plasmodium
- induced pluripotent stem cells (iPSC) – Vector-based methods for ex vivo and in vivo iPSC generation
- Gene/genome engineering – Zinc finger nucleases, TALEns, CRISPR/Cas
- non-coding RNAs – Role of miRNAs as regulators of physiology and pathogen infection
10 most important publications (lab members in bold; click here for the full list):
- F. Bubeck, M. Hoffmann, Z. Harteveld, S. Aschenbrenner, A. Bietz, M. Waldhauer, K. Börner, J. Fakhiri, C. Schmelas, L. Dietz, D. Grimm, B. Correia, R. Eils, and D. Niopek. 2018. Engineered anti-CRISPR proteins for optogenetic control of CRISPR/Cas9. Nat. Methods, 15:924-7
- E. Senís, L. Mosteiro, S. Wilkening, E. Wiedtke, A. Nowrouzi, S. Afzal, R. Fronza, H. Landerer, M. Abad, D. Niopek, M. Schmidt, M. Serrano, and D. Grimm. 2018. AAV vector-mediated in vivo reprogramming into pluripotency. Nat. Commun., 9:2651.
- T. Michler, S. Grosse, S. Mockenhaupt, N. Röder, F. Stückler, B. Knapp, C. Ko, M. Heikenwälder, U. Protzer, and D. Grimm. 2016. Blocking sense strand activity improves potency, safety and specificity of anti-hepatitis B virus short hairpin RNA. EMBO Mol. Med., 8:1082-98.
- S. Mockenhaupt, S. Grosse, D. Rupp, R. Bartenschlager, and D. Grimm. 2015. Alleviation of off-target effects from vector-encoded shRNA via co-delivered RNA decoys. PNAS, 112:E4007-16.
- N. Schürmann, L. G. Trabuco, C. Bender, R. B. Russell, and D. Grimm. 2013. Molecular dissection of human Argonaute proteins using DNA family shuffling. Nat. Struct. & Mol. Biol. 20:818-26.
- K. Börner, D. Niopek, D. (…) H.-G. Kräusslich, and D. Grimm. 2013. Robust RNAi enhancement via human Argonaute-2 overexpression from plasmids, viral vectors and cell lines. Nucleic Acids Res. 41:e199.
- D. Grimm, L. Wang, J.S. Lee, N. Schürmann, S. Gu, K. Börner, T.A. Storm, and M.A. Kay. 2010. Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liver. J. Clin. Invest. 120:3106-19.
- D. Grimm, J.S. Lee, L. Wang, T. Desai, B. Akache, T.A. Storm, and M.A. Kay. 2008. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and re-targeting of adeno-associated viruses. J. Virol. 82:5887-911.
- D. Grimm, K.S. Streetz, C.L. Jopling, T.A. Storm, K. Pandey, C.R. Davis, P. Marion, F. Salazar, and M.A. Kay. 2006. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537-41.
- D. Grimm, S. Zhou, H. Nakai, C.E. Thomas, T.A. Storm, S. Fuess, T. Matsushita, J. Allen, R. Surosky, M. Lochrie, L. Meuse, A. McClelland, P. Colosi, and M.A. Kay. 2003. Pre-clinical in vivo evaluation of pseudotyped adeno-associated virus (AAV) vectors for liver gene therapy. Blood 102:2412-9.